{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:44:16Z","timestamp":1777527856727,"version":"3.51.4"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T00:00:00Z","timestamp":1133827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prospective longitudinal examinations of anthracycline\u2010induced cardiomyopathy in a homogeneous cohort are rare in pediatric oncology. We herein report the results of observations on the frequency of cardiomyopathy in doxorubicin\u2010treated sarcoma patients in Germany, Austria, and Switzerland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Procedure<\/jats:title>\n                    <jats:p>\n                      The Late Effects Surveillance System (LESS) prospectively collects longitudinal data on late sequelae of antineoplastic therapy in Ewing\u2010, soft tissue\u2010, and osteosarcoma patients treated within the therapy trial protocols of the German Society of Pediatric Oncology and Hematology. Two hundred sixty\u2010five relapse\u2010free patients who had received doxorubicin for the treatment within the EICESS\u201092\/EURO\u2010E.W.I.N.G.\u201099, COSS\u201096, and CWS\u201096 therapy trials were serially examined by echocardiography. The analyzed population consisted of 142 males and 123 females. Their mean age at the end of therapy was 13\u2009\u00b1\u20095 years. The mean follow\u2010up time was 34\u2009\u00b1\u200912 months. The mean cumulative doxorubicin dose was 290\u2009\u00b1\u200991 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this cohort, the total cumulative incidence of doxorubicin\u2010induced cardiomyopathy was 7.5%. Four patients (1.5%) suffered from a symptomatic cardiomyopathy and 16 (6%) from a subclinical cardiomyopathy. Cardiomyopathy manifested in 11 cases already under antineoplastic therapy and in the remaining nine cases at a median of 26 days (range: 17\u2013174 days) after stopping antineoplastic therapy. Univariate and multivariable analysis did not confirm any of the known risk factors for developing anthracycline\u2010induced cardiomyopathy in our patient group within the described time interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>After a mean follow\u2010up of 34\u2009\u00b1\u200912 months, cumulative incidence of doxorubicin\u2010induced cardiomyopathy in our pediatric sarcoma patients was at the lower end of that reported by other groups. Pediatr Blood Cancer 2006, 46:489\u2013495. \u00a9 2005 Wiley\u2010Liss, Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pbc.20492","type":"journal-article","created":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T15:58:26Z","timestamp":1133884706000},"page":"489-495","source":"Crossref","is-referenced-by-count":55,"title":["Prospective longitudinal evaluation of doxorubicin\u2010induced cardiomyopathy in sarcoma patients: A report of the late effects surveillance system (LESS)"],"prefix":"10.1002","volume":"46","author":[{"given":"M.","family":"Paulides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kremers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bielack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Treuner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.D.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,6]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1046537"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.40.6.355"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.153"},{"key":"e_1_2_7_5_2","unstructured":"COSS\u201096.Cooperative Osteosarkomstudie: COSS\u201096 Studienprotokoll. Dr. Stefan Bielack Abteilung f\u00fcr p\u00e4diatrische H\u00e4matologie und Onkologie der Universit\u00e4tskilinik Hamburg\u2010Eppendorf Martinistr. 52 D\u201020246 Hamburg."},{"key":"e_1_2_7_6_2","first-page":"A842","article-title":"Improved cure rates in paediatric cancer","volume":"100","author":"Creutzig U","year":"2003","journal-title":"Deutsches \u00c4rzteblatt"},{"key":"e_1_2_7_7_2","unstructured":"CWS\u201096 5.Cooperative Weichteilsarkom Studie. CWS\u201096 Studienprotokoll. CWS\u2010Studie Olgahospital Stuttgart Bismarckstr. 8 70176 Stuttgart."},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199603000-00020"},{"key":"e_1_2_7_9_2","unstructured":"EURO\u2010E.W.I.N.G.\u201099 7.European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies EURO\u2010E.W.I.N.G.\u201099 Study Protocoll. Dr. Michael Paulussen Dept. Paed. Haematol.\/Oncology Univ. of Muenster Albert\u2010Schweizer\u2010Str. 33 D\u201048129 Muenster Germany.1999."},{"key":"e_1_2_7_10_2","first-page":"190","article-title":"Dynamic stress echocardiography in asymptomatic patients who received chemotherapy in childhood because of a malignant disease","volume":"58","author":"Elbl L","year":"2003","journal-title":"Kardiol Pol"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20015"},{"key":"e_1_2_7_12_2","first-page":"478","article-title":"Behandlung der linksventrikul\u00e4ren (LV) Dysfunktion Nach Anthracyclin\u2010Chemotherapie im Kindesalter mit einem beta\u2010Rezeptoren\u2010Blocker (Carvedilol) zur Verbesserung der LV\u2010funktion und zur Verh\u00fctung einer Progression zur Herzinsuffizienz. Protokoll f\u00fcr eine randomisierte, doppel\u2010blinde Multicenterstudie","volume":"152","author":"Franz AR","year":"2004","journal-title":"Monatsschr Kinderheilkd"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(01)00201-X"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20091"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199701)28:1<22::AID-MPO5>3.0.CO;2-V"},{"key":"e_1_2_7_16_2","first-page":"815","article-title":"The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: An experimental study","volume":"22","author":"Koutinos G","year":"2002","journal-title":"Anticancer Res"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048113"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.191"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf118"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf167"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00112-002-0524-x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(200005)34:5<348::AID-MPO6>3.0.CO;2-U"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.10325"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-836503"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506293322602"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.102"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(94)70008-7"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035153"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.1999.0128"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.56.2.6"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1058-9813(98)00008-3"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.4.208"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1043800"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601904"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-suppl_2-17"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.178"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.022"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950210704"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20016"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11274"},{"key":"e_1_2_7_41_2","first-page":"4387","article-title":"Inhibition of adriamycin cardiotoxicity by 5\u2010fluorouracil: A potential free oxygen radical scavenger","volume":"18","author":"Stathopoulos GP","year":"1998","journal-title":"Anticancer Res"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.89.5.942"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03470120074036"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(97)00114-9"},{"key":"e_1_2_7_45_2","volume-title":"The Cochrane library, Issue 3","author":"van Dalen EC","year":"2004"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.12.006"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.99.006"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20492","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T03:10:40Z","timestamp":1696648240000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,6]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1002\/pbc.20492"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20492","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.10331.467820","asserted-by":"object"}]},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,6]]}}}